Relmada Therapeutics, Inc.
RLMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $20 | $8 | $16 |
| - Cash | $1 | $1 | $1 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $19 | $7 | $12 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$10 | -$10 | -$18 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$10 | -$10 | -$18 | -$19 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -0.3 | -0.58 | -0.62 |
| % Growth | 0% | 48.3% | 6.5% | – |
| Operating Cash Flow | -$7 | -$6 | -$18 | -$9 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7 | -$6 | -$18 | -$9 |